Anthera Pharmaceuticals Inc  

(Public, NASDAQ:ANTH)   Watch this stock  
Find more results for Brent Thompson´┐Ż
3.08
+0.02 (0.65%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.01 - 3.10
52 week 2.28 - 11.25
Open 3.04
Vol / Avg. 313,858.00/572,547.00
Mkt cap 124.89M
P/E     -
Div/yield     -
EPS -1.01
Shares 40.95M
Beta 1.95
Inst. own 57%
Aug 8, 2016
Q2 2016 Anthera Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 29, 2016
Anthera Pharmaceuticals Inc Conference Call to Discuss the data from BRIGHT-SC Clinical Study
Jun 22, 2016
Anthera Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 8, 2016
Anthera Pharmaceuticals Inc at Jefferies Healthcare Conference
May 20, 2016
Anthera Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
May 9, 2016
Q1 2016 Anthera Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -8086.90% -1105.81%
Operating margin -8080.69% -1106.53%
EBITD margin - -1097.58%
Return on average assets -108.15% -136.47%
Return on average equity -133.47% -188.36%
Employees 25 -
CDP Score - -

Address

25801 Industrial Blvd Ste B
HAYWARD, CA 94545-2223
United States - Map
+1-510-8565600 (Phone)
+1-510-8565597 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Officers and directors

Christopher S. Henney Ph.D. Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Craig Thompson President, Principal Operating Officer
Age: 49
Bio & Compensation  - Reuters
Paul F. Truex President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
May Liu Senior Vice President - Finance and Administration, Principal Accounting Officer
Age: 39
Bio & Compensation  - Reuters
Klara A. Dickinson Chief Regulatory Officer, Senior Vice President
Age: 42
Bio & Compensation  - Reuters
James E. Pennington M.D. Interim Chief Medical Officer
Age: 73
Bio & Compensation  - Reuters
Brent Furse Director
Age: 47
Bio & Compensation  - Reuters
Steven B. Engle Independent Director
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Independent Director
Age: 42
Bio & Compensation  - Reuters
Philip T Sager Independent Director
Age: 59
Bio & Compensation  - Reuters